



Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.







[THEDIVIDENDPRINCE.COM](https://www.thedividendprince.com)

Price	52 week low	52 week high	Total shares outstanding	Market cap	Exchange market
62.55	62.4	148.15	4537 Millions shares	284 Billions	NYSE

Thedividendprince rating*
<b>9/10</b>

Key Metrics

Blue Chips	Yes	✓
Brand ranking**	448	✓
Revenue (CAGR) 10 years	10.40%	✓
Net income (CAGR) 10 years	11.22%	✓
EPS (CAGR) 10 years	12.83%	✓
Price earnings ratio	17.93	✓
Net Profit Margin TTM	34.78%	✓
Dividend payout ratio	43.71%	✓
Dividend yield	2.80%	✓
Return on equity (10y average)	72.62%	✓
Return on Tangible assets (10y average)	34.26%	✓
Return on Invested Capital TTM	39.07%	✓
Debt to equity (10y average)	0.20	✓
Debt to assets (10y average)	0.07	✓
Price to book ratio TTM	1.26	✓
Fair Value (Morningstar)	89	✓
Economic Moat (Morningstar)	Wide	✓
Long term debt rating (Moody's)	Aa3	✓
Short term debt rating (Moody's)	P-1	✓
Dividend Cut Risk Score	18.75%	✓
ESG Risk Rating (Morningstar)	22.97	✗
Financial Strength Score (Piotroski Score)	6	✓
Last Earning Call AI Sentiment Analysis	neutral	✗
Stock beats the ref. index for the last 10 years	✓	
steady revenue ?	✓	
Steady net income ?	✓	
Steady profit margin positive ?	✓	
Steady FCF ?	✓	
steady dividends and increasing ?	✗	
Nb of shares decreasing ?	✓	



\*Thedividendprince rating is explained here

\*\*Brand ranking source

Disclaimer :Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this document should be seen as a recommendation to follow any investment strategy. Errors may occur.